Robin/openwiki-wiki
1
0
Fork 0
Code Issues Pull Requests Actions Packages Projects Releases Wiki Activity

chore: daily update 2026-07-27

Browse Source
This commit is contained in:
OpenWiki Bot
2026-07-27 02:21:48 +08:00
parent 70c3a74a85
commit 5e20003f93
7 changed files with 138 additions and 38 deletions
Download Patch File Download Diff File Expand all files Collapse all files
sources/web-search.md
+73
View File
@@ -36,3 +36,76 @@
- Queries: 10
- Instance: `web-search-1`
- Raw evidence: `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
---
## 2026-07-26 18:07 pull
Second Tavily pull on the same day (same 10-query lane). Three lanes produced material new evidence (China regulatory, organ-on-chip/CDMO, Hermes agent model eval). CelVivo / 3Brain / Cellink lanes re-surfaced the earlier Nature papers with Tavily's *answer text* mis-attributing vendor names — flagged below.
### China CDE cell & gene therapy classification — source-backed
- **cisema.com, 2026-07-24:** [China CDE Defines Classification Rules for Cell & Gene Therapy Drugs](https://cisema.com/news/china-cell-gene-therapy-classification). China's Center for Drug Evaluation (CDE) under the National Medical Products Administration published technical guidelines defining scope and classification of cell therapy medicinal products and gene therapy medicinal products; aims to standardize CMC planning and regulatory engagement.
- **Robin relevance:** direct read for the Chinese pharma R&D / CDMO / biotech customer base. Single credible source — keep as `source-backed` until corroborated by an NMPA/CDE-direct release. Promoted to `/themes.md` row `china-cde-cell-gene-therapy-rules-2026` and `/commitments.md` as a verification item.
- Lighter signals in this lane: Roots Analysis [Cell Therapy Manufacturing Market Size 2035](https://www.rootsanalysis.com/reports/cell-therapy-manufacturing/285.html) (2026-07-24); Frontiers [pilot study of nebulized 3D-cultured MSC-derived extracellular vesicles](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1809451/full) (2026-07-24); PharmaSalmanac [Stem Cell Therapies: Close to Transforming Promise into Real Patient Outcomes](https://www.pharmasalmanac.com/articles/stem-cell-therapies-close-to-transforming-promise-into-real-patient-outcomes) (2026-07-22). Application-domain signal only — folded into the existing `class-organoid-3d-bioprinting` row evidence.
### Organ-on-chip / CDMO collaboration / ADLM 2026 — source-backed
- **BioSpace, 2026-07-24:** [Phillips Medisize to Present Strategies for Scaling Complex In Vitro Diagnostic (IVD) Builds Through Structured CDMO Collaboration at ADLM 2026](https://www.biospace.com/press-releases/phillips-medisize-to-present-strategies-for-scaling-complex-in-vitro-diagnostic-ivd-builds-through-structured-cdmo-collaboration-at-adlm-2026). Top score (0.413) — frames CDMO collaboration as the path to scaling complex IVD / organ-on-chip workflows.
- **BioSpace, 2026-07-24:** [AcroCyte Therapeutics Awarded ARPA-H Funding to Advance Scalable Human Organoid Technologies](https://www.biospace.com/press-releases/acrocyte-therapeutics-awarded-arpa-h-funding-to-advance-scalable-human-organoid-technologies). 0.215 score. ARPA-H backing for scalable human-organoid platforms — application-domain signal for CelVivo-class bioreactor positioning.
- **Nature, 2026-07-24:** [Engineering etiology-aligned in vitro models of human vessels](https://www.nature.com/articles/s41378-026-01397-9). 0.165 score. Disease-specific in vitro vessel models — organoid/3D-cell-culture adjacent.
- **BioSpace, 2026-07-23:** [Roche showcases intelligent lab solutions and high-precision instruments at ADLM 2026](https://www.biospace.com/press-releases/roche-showcases-intelligent-lab-solutions-and-high-precision-instruments-at-adlm-2026-to-help-laboratories-address-workforce-and-workflow-challenges). 0.151 score. Industry context, not vendor-anchored to Robin's 4 lines.
### Hermes Agent best-models eval — source-backed (workflow tooling, low priority)
- **haimaker.ai, 2026-07-23:** [Best Models for Hermes Agent (July 2026): Tested & Ranked](https://haimaker.ai/blog/best-models-for-hermes-agent). 0.731 score. Third-party ranking of LLMs for Hermes Agent usage — Robin-relevant as the daily-driver stack. Folds into the existing `MiniMax-m3` theme row last-seen.
- **Reddit, 2026-07-22:** [What are you USE CASES for Hermes Agent?](https://www.reddit.com/r/hermesagent/comments/1v34auv/what_are_you_use_cases_for_hermes_agent). 0.424 score. User-driven Hermes use cases; not a vendor-anchored signal.
- **Data-quality flag:** Tavily's synthesized *answer* for this lane hallucinated detail ("streaming robustness, REPL UX improvements, and provider hardening") — none of those bullets appear in the haimaker article. Treat Tavily's answer text as untrusted.
### CelVivo / 3Brain / Cellink / CellShot lanes — same Nature results, Tavily answer text mis-attributed
- **CelVivo ClinoReactor / Cellink BIO X:** the Nature [MO:BOT liver-spheroid automation paper](https://www.nature.com/articles/s41598-026-58939-4) reappears at score 0.402 (CelVivo lane) and 0.074 (Cellink lane). Tavily's answer text describes MO:BOT but labels the platform "ClinoReactor" / "BIO X" — vendor attribution is **wrong**. Treat the result as the MO:BOT paper, not a CelVivo or Cellink product claim.
- **3Brain CorePlate MEA:** the Nature [portable semi-dry EEG device paper](https://www.nature.com/articles/s41598-026-52672-8) reappears at score 0.187. Tavily's answer text labels it "3Brain CorePlate MEA 2026" — this is wrong; the paper is about an EEG headset, not 3Brain's MEA chips. Do not promote as 3Brain evidence.
- **CellShot / CellPick:** Cellares–Papillon partnership (Cellares is unrelated to Femtobiomed) and CCDx liquid biopsy — no direct Femtobiomed result in either pull.
- **CelVivo installed-base:** no direct result; pull dominated by Cepheid GeneXpert noise. Query phrasing needs a vendor-name anchor to retrieve CelVivo-specific results.
### OpenWiki / RAGFlow / agent-memory-wiki lanes — Tavily recall broken
- "OpenWiki connectors Tavily RAGFlow 2026" returned SmartBall X pipeline inspection, AWWA ACE26, insurance backchat, helicopter partnership, OLED manufacturing equipment, and fashion-show slides. None of the 8 results touches Robin's actual stack (OpenWiki / Gitea / Wiki.js / RAGFlow / NocoDB / SeaFile). Skip until the query is rephrased.
- "Agent personal memory wiki 2026" returned an Australian enterprise data-AI survey (0.403), a LangChain4j self-building-agent experiment (0.168), and ad-agency awards — no direct personal-wiki / OpenWiki-self evidence. Adjacent only.
## Source coverage (cumulative)
- Pull 1: fetched 2026-07-26T17:39:11Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T17-38-33-286Z/web-search-results.json`
- Pull 2: fetched 2026-07-26T18:07:27Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-07-14-335Z/web-search-results.json`
- Pull 3: fetched 2026-07-26T18:16:21Z — raw `~/.openwiki/connectors/web-search/raw/2026-07-26T18-16-06-804Z/web-search-results.json`
- Queries: pull 1 + pull 2 = 10 queries each; pull 3 = 6 queries (vendor-anchored only)
- Instance: `web-search-1`
---
## 2026-07-26 18:16 pull
Third Tavily pull on the same day, after the 2026-07-27 `~/.openwiki/INSTRUCTIONS.md` scope was loaded. The query lane was narrowed from 10 vendor-mixed queries to **6 vendor-anchored queries**, dropping the China-cell-therapy regulation lane (now stale-pinned via `/commitments.md`), the Hermes Agent / MiniMax M3 daily-driver lane, and the OpenWiki/RAGFlow/agent-memory lanes (the latter two were already noise per the prior pulls).
### Queries and top results
| Query | Top hits | Score | Vendor-anchor |
| --- | --- | --- | --- |
| `CelVivo ClinoReactor spheroid new paper 2026` | Nature MO:BOT liver-spheroid automation paper (re-mention); Patient-Derived Tumor Organoids for personalizing cancer treatment; CCDx whole-cell genomic profiling | 0.44 / 0.11 / 0.05 | no — MO:BOT, not CelVivo; organoid application only |
| `3Brain CorePlate MEA neuron 2026` | News-Medical.net "New imaging platform tracks hundreds of neurons at unprecedented depths"; BioSpace brain-remodeling-during-adolescence; MobiHealthNews first able-bodied BCI recipients | 0.20 / 0.10 / 0.08 | no — generic neuroscience imaging, not 3Brain CorePlate |
| `Cellink BIO X bioprinter clinical 2026` | Roche ADLM 2026 intelligent lab solutions; 10x Genomics CLIA lab + Cleveland Clinic; Massive Bio FOMAT cancer prescreening | 0.11 / 0.09 / 0.07 | no — industry context; 10x / Massive Bio unrelated to Cellink |
| `organoid-on-chip pharmacology 2026` | AcroCyte Therapeutics ARPA-H funding for scalable human-organoid tech (re-mention, score up to 0.617 from 0.215); Patient-Derived Tumor Organoids; Nature MO:BOT liver-spheroid | 0.62 / 0.41 / 0.35 | no — AcroCyte is application, not one of Robin's 4 vendors |
| `CellShot CellPick bioprinter research 2026` | Cellares–Papillon PPL-001 automation partnership (re-mention); CCDx whole-cell genomic profiling; Genetic Engineering AI protein-engineering for biomanufacturing | 0.17 / 0.14 / 0.08 | no — Cellares/Papillon unrelated to Femtobiomed |
| `lab automation assay workflow news 2026` | Roche ADLM 2026; Nature MO:BOT liver-spheroid; Cepheid third-generation GeneXpert at ADLM 2026 | 0.82 / 0.74 / 0.56 | no — Roche/Cepheid industry context, not vendor-anchored |
### Synthesis result
- **No new vendor-anchored evidence** — every query's top hit is either (a) application/organoid-level without naming Robin's 4 vendors, (b) a re-mention of an item already in the 17:38 or 18:07 pull, or (c) an unrelated industry/competitor brand (Roche, Cepheid, 10x, Cellares, Massive Bio, CCDx).
- **AcroCyte ARPA-H** reappears at 0.617 (up from 0.215 in the 18:07 pull). Same item, stronger score — the existing `/themes.md` `class-organoid-3d-bioprinting` row already covers it via the ARPA-H funding evidence; no new row needed.
- **Tavily answer-text vendor mis-attribution continues.** The `CelVivo ClinoReactor spheroid new paper 2026` answer text describes MO:BOT but labels it "ClinoReactor"; the `3Brain CorePlate MEA neuron 2026` answer text points at generic brain-imaging news without anchoring to CorePlate. Treat Tavily answer text as untrusted and only the underlying URLs as evidence.
- **Dropped lanes** (vs. pull 2): `China cell therapy 3D bioprinting regulation 2026` (China CDE item still anchored in `/commitments.md` as `china-cde-cell-gene-therapy-rules-2026`); `Hermes Agent MiniMax M3 changelog 2026` (already in `/themes.md` `MiniMax-m3` row); `OpenWiki connectors Tavily RAGFlow 2026` (noise); `agent personal memory wiki 2026` (noise). Existing rows on `/themes.md` and `/commitments.md` are unchanged because their evidence sources (Tavily pull 2, HN pull 18:00) are still on disk and referenceable.
### Coverage note for next update
The China CDE regulatory lane is no longer being refreshed on every Tavily pull. The existing `/commitments.md` item pins it as `source-backed` with one credible cisema.com source. If a future Tavily or HN pull surfaces an NMPA / CDE-direct corroboration, promote from watchlist to `source-backed` and move into `/themes.md` as a confirmed row.